| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Bromobenzimidazole has been found to bind to the bromodomain of proteins, inhibiting protein synthesis and leading to cell death by apoptosis. Bromodomains are epigenetic readers that recognize acetylated lysine residues on histones, and their inhibition is a target for cancer and inflammatory diseases. The compound also acts as an inhibitor of human cytomegalovirus (HCMV) by interfering with viral DNA replication processes.
|
|---|---|
| ln Vitro |
In vitro, 2-bromobenzimidazole is primarily used as a biochemical reagent and synthetic intermediate. It has been reported to have antiproliferative activity on tumor cell lines, suggesting that it may induce cell death or inhibit cell growth. The compound shows potential as an antimicrobial agent, cancer treatment, and as a drug for inflammatory diseases. It is also used as a sulfonylation reagent for organic synthesis and drug discovery.
|
| ln Vivo |
In vivo data for 2-bromobenzimidazole as a therapeutic agent are limited. The compound has been studied for its potential as an antimicrobial and antiviral agent, but specific in vivo efficacy and pharmacokinetic data are not well-documented. Its in vivo relevance is primarily indirect, through the biological activities of the final pharmaceutical compounds derived from its benzimidazole scaffold.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, 2-bromobenzimidazole can be evaluated for binding to bromodomains. Standard protocols involve incubating the compound with recombinant bromodomain proteins and measuring binding affinity using fluorescence polarization (FP) or AlphaScreen assays. The compound's ability to displace a fluorescently labeled acetylated peptide from the bromodomain is quantified. IC₅₀ values are calculated from dose-response curves to determine inhibitory potency against specific bromodomain targets.
|
| Cell Assay |
For in vitro cell-based experiments, 2-bromobenzimidazole is evaluated for antiproliferative and apoptotic activity against cancer cell lines. Cells are seeded in 96-well plates and treated with the compound at various concentrations (typically 0.1-100 µM) for 24-72 hours. Cell viability is assessed using MTT or resazurin-based assays. Apoptosis is measured using flow cytometry with Annexin V/PI staining. Antiviral activity against HCMV can be assessed using plaque reduction assays.
|
| Animal Protocol |
In vivo animal studies for 2-bromobenzimidazole are limited. For potential anticancer or antiviral candidates derived from this scaffold, efficacy studies would typically be performed in mouse xenograft models of cancer or in viral challenge models. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of tumor volume, viral load, or survival as endpoints. Specific protocols for this compound are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-bromobenzimidazole are not extensively characterized. The compound has a molecular weight of 197.03 g/mol, which is favorable for oral bioavailability. The bromine atom may influence metabolic stability and lipophilicity. As a benzimidazole derivative, it is expected to have reasonable membrane permeability. Empirical pharmacokinetic data such as half-life, clearance, volume of distribution, and oral bioavailability are not available in the public literature.
|
| Toxicity/Toxicokinetics |
2-Bromobenzimidazole is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
2-Bromobenzimidazole (CAS 54624-57-6) is primarily a research-grade chemical intermediate and biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for antimicrobial and antiviral agents, as a bromodomain inhibitor for cancer and inflammatory disease research, and as a sulfonylation reagent for organic synthesis and drug discovery. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C7H5BRN2
|
|---|---|
| Molecular Weight |
197.03
|
| Exact Mass |
195.963
|
| CAS # |
54624-57-6
|
| PubChem CID |
2776281
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
346.0±25.0 °C at 760 mmHg
|
| Melting Point |
208ºC
|
| Flash Point |
163.0±23.2 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.728
|
| LogP |
2.75
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
129
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=NC2=C(N1)C=CC=C2
|
| InChi Key |
PHPYXVIHDRDPDI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H5BrN2/c8-7-9-5-3-1-2-4-6(5)10-7/h1-4H,(H,9,10)
|
| Chemical Name |
2-bromo-1H-benzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0754 mL | 25.3768 mL | 50.7537 mL | |
| 5 mM | 1.0151 mL | 5.0754 mL | 10.1507 mL | |
| 10 mM | 0.5075 mL | 2.5377 mL | 5.0754 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
